U.S. CAR-T Cell Therapy Market Size, Share & COVID-19 Impact Analysis, By Drug (Yescarta, Tecartus, Carvykti, Abecma, Breyanzi, Kymriah, and Others), By Indication (Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma (NHL), and Multiple Myeloma), By End-user (Hospitals and Oncology Treatment Centers), and Country Forecast, 2023-2030

The U.S. CAR-T cell therapy market size was worth USD 1.60 billion in 2022 and is projected to grow at a CAGR of 24.8% during the forecast period.

Chimeric antigen receptor (CAR) T cell therapy is a novel way to enable the T cells by modifying them in the lab so that they can easily target antigens and destroy the cancer cells. There is a significant rise in the incidence of different types of cancer, including leukemia, melanoma, and multiple myeloma, has led to a growing number of adults seeking treatment in the U.S.

• For instance, according to 2023 article published by the National Cancer Institute, it was reported that more than 1.2 million Americans develop cancer each year in the U.S.

Furthermore, growing awareness of novel therapies has prompted key players to invest in research and development activities for this therapy, expecting an increase in the U.S. CAR-T cell therapy market share.

The growing approvals for various cell-based therapies resulted in a rising treatment rate among patients, contributing to the growth of the market. The emergence of the COVID-19 pandemic minimally impacted the U.S. CAR-T cell therapy market. This was due to limited clinical trials along with reduced diagnosis among patients, due to a major focus shifted toward COVID-19 patients. However, key players witnessed an increase in revenue owing to some patients underwent CAR-T cell treatment therapies during the pandemic.

U.S. CAR-T Cell Therapy Market Trends

Growing Research and Development Activities for Cell-Based Therapies

In recent years, the market has witnessed an increasing demand for cancer treatment among patients owing to the rising prevalence of various types of cancer. Scientific advancements are leading to the introduction of technologies and therapies to overcome existing challenges in the country. Therefore, rising focus of key players on investment for research and development activities is anticipated to drive the growth of the market.

• For instance, according to a 2022 article published by Cell & Gene, it was reported that there were 750 active CAR-T therapies in development across the globe. Amongst these, 375 are in their clinical phases and the rest are in the preclinical stage.

U.S. CAR-T Cell Therapy Market Growth Factors

Increasing Prevalence of Cancer among Population to Spur Market Growth

The growing prevalence of various types of cancer, including leukemia, and others, is stimulating the market players to increase their focus on technological advancements, along with growing product approvals are anticipated to support the growth of the market. According to a 2020 article published by Biomed Central Ltd., a clinical trial for a technology named FasT CAR-T decreased the T cell manufacturing time at the laboratories to 24 hours. This trial is currently under Phase I.

• For instance, in March 2022, according to the National Cancer Institute, it was reported that the Food and Drug Administration (FDA) approved Carvykti (ciltacabtagene autoleucel), a personalized immunotherapy, for adults suffering from multiple myeloma and are not responding to any other treatment.

RESTRAINING FACTORS

High Cost Associated with CAR-T Cell Therapy Might Hinder the Market Growth

Despite the increasing adoption of CAR-T cell therapy among the patient population in the country, the high cost associated with this therapy might hamper its demand in the U.S. market. Along with this, factors such as the availability and time required for T cells manufacturing are among the additional constraints restraining the growth of the market.

• For instance, according to a 2022 article published by the National Cancer Institute, it was reported that cilta-cel (ciltacabtagene autoleucel) CAR-T cell therapy had a list price of USD 465,000.0 for a one-time infusion.

In the U.S., about 10 CAR-T cell therapies received approval by U.S. FDA in 2023. Among these four drugs approved were for oncology, two were for hemophilia, and two were for muscular disorders.

U.S. CAR-T Cell Therapy Market Segmentation Analysis

By Drug Analysis

Based on drug, the market is segmented into yescarta, tecartus, carvykti, abecma, breyanzi, kymriah, and others.

The yescarta segment held the largest share in 2022 owing to certain benefits of this therapy, including a longer survival rate, reduction in the risk of death, and improvement in the condition, and other benefits. Along with this, the approval of the therapy for advanced types of cancer is anticipated to spur the growth of the market. 

For instance, in June 2023, Giled Sciences, Inc. reported that Yescarta resulted in a 27.4% reduction in the risk of death and a 38% improvement in overall survival, as demonstrated in the Phase-3 ZUMA 7 clinical study of Yescarta CAR- T cell therapy.

By Indication Analysis

Based on indication, the market is segmented into acute lymphhoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma.

The multiple myeloma segment is projected to grow at the highest CAGR during the forecast period; 2023-2030. The highest CAGR is due to the increasing prevalence of multiple myeloma among children and adults. Along with this, rising approval of therapies is anticipated to boost the market growth. 

• For instance, according to data published by the American Cancer Society, it was reported that the lifetime risk of getting multiple myeloma is 1 in 132 people.

By End User Analysis

Based on end user, the market is segmented into hospitals, and oncology treatment centers.

The hospitals held the largest share in 2022 owing to the rising inpatient and outpatient admissions resulting in a growing rate of diagnosis, further increasing the demand for the introduction of advanced therapies in the market. Furthermore, the presence of a larger number of hospitals in the country is expected to drive segmental growth in the long run.

• For instance, in October 2022, according to the American Hospital Association (AHA), it was reported that there are about 6,093 hospitals in the U.S.

List of Key Companies in U.S. CAR-T Cell Therapy Market

In terms of the competitive landscape, the U.S. CAR-T cell therapy market growth is attributed to the presence of established and emerging companies operating in the market. Leading market players, such as Novartis AG, Ferring B.V., and Johnson & Johnson Services, Inc. hold a significant share in the market. These companies’ apex position is attributed to the strong research and development activities coupled with the increasing number of product launches. Furthermore, a growing focus on receiving product approvals and the entry of new players entering into the CAR-T cell therapy market are expected to boost their market position.

• For instance, In February 2022, the U.S. FDA approved CARVYKTI, Janssen’s cell therapy for  treatment of adults suffering from relapsed or refractory multiple myeloma (RRMM), with an aim to cater for the rising demand among patients.

Some other companies with a direct presence in the U.S. market include Gilead Sciences, Inc.,  Bristol-Myers Squibb Company, bluebird bio, Inc., and others are focusing on strategic moves, such as collaborations and acquisitions among other market players , aiming to attract more market revenue.

LIST OF KEY COMPANIES PROFILED:

• Bristol-Myers Squibb Company (U.S.)


• Ferring B.V. (Switzerland)


• Johnson & Johnson Services, Inc.  (U.S.)


• Novartis AG (Switzerland)


• Spark Therapeutics, Inc. (U.S.)


• Enzyvant Therapeutics GmbH (U.S.)


• bluebird bio, Inc. (U.S.)


• Gilead Sciences, Inc. (U.S.)


• CARsgen Therapeutics Holdings Limited (China)

KEY INDUSTRY DEVELOPMENTS:

• May 2023 – Janssen Biotech collaborated with Cellular Biomedicine Group (CBMG) for the development of next-generation CAR-T cell therapies for patients suffering from B cell malignancies. With this collaboration, the company gained all rights for the development and commercialization of CBMG’s CART-T assets, C-CAR039, and C-CAR066.


•  June 2022 –  The U.S. Food and Drug Administration approved Bristol Myers Squibb CAR T cell therapy Breyanzi for patients suffering relapsed or refractory large B cell lymphoma and is not compatible with transplants. The approval aimed to support the diverse needs of the patient population.


• March 2021 – U.S. FDA approved Bristol Myers Squibb’s and Blubird Bio’s Abecma for patients suffered from relapsed or refractory multiple myeloma, meeting the increasing treatment demand among the patient population.

REPORT COVERAGE

The U.S. CAR-T cell therapy market report provides a detailed analysis of the market, focusing on key aspects, such as an overview of the technological advancements and the prevalence of different cancer in the U.S. Additionally, it includes an overview of the reimbursement and regulatory scenario for various therapies, key industry developments such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. Besides this, the report also offers insights into the unique business models of major players. Additionally, it encompasses a comparative analysis of the product portfolio of key companies and an overview of technological advancements in CAR-T cell therapy.

Report Scope & Segmentation